Filing summary
Issuer identification: The supplied filing identifies the registrant as Amarillo Biosciences, Inc., not Ainos, Inc. It is a Form 10-K for the fiscal year ended December 31, 2014; the filing text does not provide standalone fourth-quarter results.
Business context and reporting period
Amarillo was a small biopharmaceutical research and development company focused on low-dose oral interferon and the Maxisal dry-mouth supplement. It filed for Chapter 11 in October 2013 and implemented its reorganization plan on November 20, 2014. The bankruptcy case was closed in February 2015. Fresh-start accounting created a new reporting entity as of November 20, so successor and predecessor financial statements are not directly comparable. Management also presents combined full-year 2014 results as supplementary, non-GAAP information.
Financial performance and position
- Revenue: No revenue in 2014 or 2013; no products were produced or sold. Gross margin was therefore zero and operating margins are not meaningful.
- 2014 earnings: Combined full-year net income was $2.84 million, compared with a $623,000 net loss in 2013. The 2014 profit primarily reflected $3.42 million of debt-forgiveness income from the reorganization, not operating revenue. GAAP periods show a $2.91 million predecessor net income through November 20 and a $70,000 successor net loss thereafter.
- Operating costs: Management’s combined full-year figures show SG&A of $565,976, up 31% from $433,193 in 2013, including $108,117 of reorganization expense. R&D fell 89% to $15,270 from $132,962, largely because there was no R&D in the last three quarters of 2014.
- Cash flow: Combining the reported predecessor and successor periods, operating cash use was approximately $555,000, investing cash use approximately $10,600, and financing provided $877,597. Cash rose from $6,539 at year-end 2013 to $318,556 at year-end 2014.
- Liquidity and debt: Year-end current assets were $335,438 and current liabilities $302,277, yielding working capital of $33,161. Total liabilities were $452,277, including $150,000 of long-term related-party debt. The reorganization reduced reported debt from $4.79 million to $452,277. Most assets were pledged as collateral for Yang-related debt.
- Equity and capital: Stockholders’ deficit was $30,742 at year-end. The Yang Group received 16,115,848 shares in the debt exchange and owned approximately 80% of the 20,144,810 shares outstanding. Management estimated post-reorganization financing needs of $1.0–$1.6 million.
Material changes, outlook, and risks
- The 2014 earnings turnaround was driven by bankruptcy debt forgiveness; the company continued to have no revenue and incurred operating losses. Auditors cited substantial doubt about its ability to continue as a going concern, owing to recurring losses and the need for additional financing.
- The company’s prior supplier stopped producing natural human interferon in 2012. Amarillo had no current source for clinical development or commercialization, and said existing study data might need to be repeated using recombinant interferon. Finding a supplier, testing, and regulatory approval could be costly and time-consuming.
- No ongoing clinical studies were reported. Management said meaningful revenue was not expected before the last quarter of 2015, or possibly later. FDA approval is required for drug commercialization.
- Management hoped to obtain financing and support from Yang, but Yang was not obligated to provide it. Failure to secure acceptable financing could impair operations or lead to cessation of business.
- Patent life and product economics were material concerns: some core patents were nearing expiration, while the Maxisal raw-material price increase had made manufacturing and sales less attractive. The company also warned that its reported tax-loss attributes might be limited or unusable.
- The common stock traded as a penny stock. A 1-for-19 reverse split and issuance of shares to Yang substantially changed ownership; common dividends were not planned.
Important facts for investors to verify
- Confirm issuer identity and filing: the supplied text is Amarillo Biosciences, Inc.’s 2014 Form 10-K, not a filing identified as Ainos, Inc.
- Review the complete financial statements and notes, including the distinction between GAAP predecessor/successor periods and management’s combined non-GAAP 2014 figures.
- Assess cash burn, near-term financing requirements, and whether Yang provided or committed additional funding after year-end.
- Verify the status and terms of Yang’s secured claim, the remaining debt, and the collateral supporting it.
- Check whether a replacement interferon source, clinical development plan, regulatory pathway, and viable product revenue were secured after the reporting date.
- Evaluate patent expiration dates, ownership and licensing terms, and the practical value of the disclosed tax-loss carryforwards.